Engineering a Clinically Translatable Bioartificial Pancreas to Treat Type I Diabetes

Gorka Orive; Dwaine Emerich; Ali Khademhosseini; Shinichi Matsumoto; R M Hernández; J L Pedraz; Tejal Desai; Riccardo Calafiore; Paul de Vos

doi:10.1016/j.tibtech.2018.01.007

Engineering a Clinically Translatable Bioartificial Pancreas to Treat Type I Diabetes

Trends Biotechnol. 2018 Apr;36(4):445-456. doi: 10.1016/j.tibtech.2018.01.007. Epub 2018 Feb 15.

Authors

Gorka Orive¹, Dwaine Emerich², Ali Khademhosseini³, Shinichi Matsumoto⁴, R M Hernández⁵, J L Pedraz⁵, Tejal Desai⁶, Riccardo Calafiore⁷, Paul de Vos⁸

Affiliations

¹ NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain; University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, Spain; BTI Biotechnology Institute, Vitoria, Spain; Joint first authors and contributed equally to the paper. Electronic address: gorka.orive@ehu.eus.
² NsGene,225 Chapman Street, Providence, RI, USA; Joint first authors and contributed equally to the paper.
³ Department of Bioengineering, Department of Chemical and Biomolecular Engineering, Henry Samueli School of Engineering and Applied Sciences, University of California-Los Angeles, Los Angeles, CA, USA; Department of Radiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, USA; California NanoSystems Institute (CNSI), University of California-Los Angeles, Los Angeles, CA, USA. Electronic address: http://twitter.com/@khademh.
⁴ Research and Development Center, Otsuka Pharmaceutical Factory, 115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima 772-8601, Japan.
⁵ NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain.
⁶ University of California, San Francisco, Department of Bioengineering and Therapeutic Sciences, Byers Hall Room 203C, MC 2520, 1700 4th Street, San Francisco, CA, USA.
⁷ Department of Medicine, Section of Cardiovascular, Endocrine and Metabolic Clinical Physiology, Laboratory for Endocrine Cell Transplants and Biohybrid Organs, University of Perugia, Piazzale Gambuli, Perugia, Italy; Joint first authors and contributed equally to the paper.
⁸ University of Groningen, Pathology and Medical Biology Section, Immunoendocrinology, Groningen, The Netherlands. Electronic address: p.de.vos@umcg.nl.

PMID: 29455936
DOI: 10.1016/j.tibtech.2018.01.007

Abstract

Encapsulating, or immunoisolating, insulin-secreting cells within implantable, semipermeable membranes is an emerging treatment for type 1 diabetes. This approach can eliminate the need for immunosuppressive drug treatments to prevent transplant rejection and overcome the shortage of donor tissues by utilizing cells derived from allogeneic or xenogeneic sources. Encapsulation device designs are being optimized alongside the development of clinically viable, replenishable, insulin-producing stem cells, for the first time creating the possibility of widespread therapeutic use of this technology. Here, we highlight the status of the most advanced and widely explored implementations of cell encapsulation with an eye toward translating the potential of this technological approach to medical reality.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Bioartificial Organs*
Clinical Trials as Topic
Diabetes Mellitus, Experimental / therapy*
Diabetes Mellitus, Type 1 / therapy*
Humans
Insulin-Secreting Cells / chemistry
Insulin-Secreting Cells / transplantation
Materials Testing
Membranes, Artificial
Models, Animal
Pancreas, Artificial*
Tissue Engineering*

Substances

Membranes, Artificial